RESUMO
Background: Chronic disseminated candidiasis (CDC) classically occurs after profound and prolonged neutropenia. The aim of the CANHPARI study was to assess the clinical value of adding 18F-fluorodeoxyglucose PET/CT to conventional radiology for initial and subsequent evaluations of CDC. Materials and methods: A pilot prospective study was conducted in 23 French onco-hematological centers from 2013 to 2017 (NCT01916057). Patients ≥ 18 y.o. suspected for CDC on abdominal conventional imaging (CT or MRI) were included. PET/CT and conventional imaging were performed at baseline and month 3 (M3). Follow-up was assessed until M12. The primary outcome measure was the global response at M3, i.e., apyrexia and complete response to PET/CT. The secondary outcome measure consists in comparison between responses to PET/CT and conventional imaging at diagnosis and M3. Results: Among 52 included patients, 44 were evaluable (20 probable and 24 possible CDC); 86% had acute leukemia, 55% were male (median age 47 years). At diagnosis, 34% had fever and conventional imaging was always abnormal with microabscesses on liver and spleen in 66%, liver in 25%, spleen in 9%. Baseline PET/CT showed metabolic uptake on liver and/or spleen in 84% but did not match with lesion localizations on conventional imaging in 32%. M3 PET/CT showed no metabolic uptake in 13 (34%) patients, 11 still having pathological conventional imaging. Global response at M3 was observed in eight patients. Conclusion: Baseline PET/CT does not replace conventional imaging for initial staging of CDC lesions but should be performed after 3 months of antifungal therapy. Clinical trial registration: [www.clinicaltrials.gov], identifier [NCT01916057].
RESUMO
Chronic disseminated candidiasis (CDC) is a rare and difficult-to-treat invasive fungal disease occurring mainly after prolonged and profound neutropenia. We describe the case of a 59-year-old man successfully treated with thalidomide for CDC recurrences after an autologous transplantation. We add evidence of the effectiveness of immunomodulatory drugs to manage inflammatory reconstitution immune syndrome-related refractory CDC.
Assuntos
Transplante de Medula Óssea/efeitos adversos , Candida albicans/isolamento & purificação , Candidíase/tratamento farmacológico , Glucocorticoides/uso terapêutico , Doença de Hodgkin/cirurgia , Síndrome Inflamatória da Reconstituição Imune/tratamento farmacológico , Imunossupressores/uso terapêutico , Talidomida/uso terapêutico , Antifúngicos/administração & dosagem , Antifúngicos/uso terapêutico , Candidíase/diagnóstico por imagem , Candidíase/imunologia , Doença Crônica , Fluconazol/administração & dosagem , Fluconazol/uso terapêutico , Glucocorticoides/administração & dosagem , Glucocorticoides/efeitos adversos , Doença de Hodgkin/complicações , Humanos , Síndrome Inflamatória da Reconstituição Imune/diagnóstico por imagem , Síndrome Inflamatória da Reconstituição Imune/imunologia , Imunossupressores/administração & dosagem , Imunossupressores/efeitos adversos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Neutropenia/complicações , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Recidiva , Talidomida/administração & dosagem , Talidomida/efeitos adversos , Transplante Homólogo/efeitos adversos , Resultado do TratamentoRESUMO
BACKGROUND: Optimal management of eumycetoma, a severely debilitating chronic progressive fungal infection of skin, disseminating to bone and viscera, remains challenging. Especially, optimal antifungal treatment and duration are ill defined. METHODOLOGY/PRINCIPAL FINDINGS: We conducted a monocentric retrospective study of 11 imported cases of eumycetoma treated by voriconazole or posaconazole for at least 6 months. Response to treatment was assessed through evolution of clinical and magnetic resonance imaging (MRI). (1â3) ß-D-glucan (BG) and positron emission tomography using [18F] fluorodeoxyglucose (PET/CT) results were also assessed. Identified species were Fusarium solani complex (nâ=â3); Madurella mycetomatis, (nâ=â3), and Exophiala jeanselmei, (nâ=â1). Moreover, two coelomycetes and one phaeohyphomycetes strains without species identification were retrieved. Serum BG and PET/CT were abnormal in 7/8 and 6/6 patients tested, respectively. Patients received last generation azoles for a mean duration of 25.9±18 months. Complete response (major clinical and MRI improvement) was observed in 5/11 patients, partial response (minor MRI improvement or stable MRI findings) in 5 and failure (MRI evidence of disease progression) in one, with a 73±39 [6-132] months mean follow-up. Relapse occurred in 2 patients after treatment discontinuation. Optimal outcome was associated with fungal species, initiation of last generation triazole therapy (<65 months since first symptoms), negative serum BG and PET/CT normalization. CONCLUSIONS/SIGNIFICANCE: MRI, PET/CT and serum BG appear as promising tools to assess optimal time of antifungal treatment for eumycetoma.
Assuntos
Antifúngicos/uso terapêutico , Micetoma/tratamento farmacológico , Triazóis/uso terapêutico , Voriconazol/uso terapêutico , Adolescente , Adulto , Criança , Exophiala/efeitos dos fármacos , Fluordesoxiglucose F18 , Fusarium/efeitos dos fármacos , Humanos , Madurella/efeitos dos fármacos , Imageamento por Ressonância Magnética , Masculino , Micetoma/diagnóstico , Micetoma/microbiologia , Tomografia por Emissão de Pósitrons , Proteoglicanas , Estudos Retrospectivos , Pele/microbiologia , Resultado do Tratamento , Adulto Jovem , beta-Glucanas/sangueRESUMO
BACKGROUND: We aimed to evaluate the additional information of 18 fluorodeoxyglucose (FDG) arterial uptake with respect to other conventional cardiovascular risk factors and arterial calcifications in patients with stable cancer. METHODS AND RESULTS: We compared the rate of cardiovascular events in 2 groups of patients with (n = 45) and without (n = 56) enhanced arterial 18FDG uptake, matched for the main clinical parameters. The extent and intensity of 18FDG uptake were quantified. A calcification index was also determined. About one third of the selected patients had a history of cardiovascular events and thus could be defined as "vulnerable patients." Old cardiovascular events (>6 months before or after positron emission tomography [PET]) and recent cardiovascular events (<6 months before or after PET) were significantly more frequent in the high-FDG uptake group than in the low-FDG uptake group (48% vs 15%, respectively [P = .0006], and 30% vs 1.8%, respectively [P = .0002]). The extent of 18FDG arterial uptake was the unique factor significantly related to the occurrence of a recent event by either logistic regression or discriminant analysis (P = .004 for all). Conversely, calcium index was the single factor related to old events (P = .004 and P = .002, respectively). CONCLUSIONS: Extensive arterial 18FDG uptake might be an indicator of an evolving atherosclerotic process and should be mentioned in PET/computed tomography reports.
Assuntos
Aterosclerose/diagnóstico por imagem , Aterosclerose/metabolismo , Fluordesoxiglucose F18/farmacocinética , Neoplasias/diagnóstico por imagem , Neoplasias/metabolismo , Tomografia por Emissão de Pósitrons/métodos , Medição de Risco/métodos , Artérias/diagnóstico por imagem , Artérias/metabolismo , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Compostos Radiofarmacêuticos/farmacocinética , Fatores de RiscoRESUMO
Iodine-123 metaiodobenzylguanidine (MIBG) cardiac scintigraphy is a useful tool for the assessment of cardiac adrenergic neuronal function, which is impaired in children with idiopathic dilated cardiomyopathy (DCM). In adults with DCM, long-term treatment with carvedilol improves both cardiac adrenergic neuronal function and left ventricular function. The aim of this prospective study was to evaluate the impact of carvedilol on cardiac adrenergic neuronal function using 123I-MIBG scintigraphy and on left ventricular function using equilibrium radionuclide angiography in children with DCM. Seventeen patients (11 female, six male; mean age 39 +/- 57 months, range 1-168 months) with DCM and left ventricular dysfunction underwent 123I-MIBG cardiac scintigraphy and equilibrium radionuclide angiography before and after a 6-month period of carvedilol therapy. A static anterior view of the chest was acquired 4 h after intravenous injection of 20-75 MBq of 123I-MIBG. Cardiac neuronal uptake of 123I-MIBG was measured using the heart to mediastinum count ratio (HMR). Radionuclide left ventricular ejection fraction (LVEF) was assessed following a standard protocol. MIBG cardiac uptake and left ventricular function respectively increased by 38% and 65% after 6 months of treatment with carvedilol (HMR=223% +/- 49% vs 162% +/- 26%, P<0.0001, and LVEF=43% +/- 17% vs 26% +/- 11%, P<0.0001). Carvedilol can improve cardiac adrenergic neuronal and left ventricular function in children with dilated cardiomyopathy. Further studies are needed to assess the relationship between improvement in MIBG cardiac uptake and the beneficial effects of carvedilol on morbidity and mortality.
Assuntos
3-Iodobenzilguanidina , Fibras Adrenérgicas/efeitos dos fármacos , Carbazóis/uso terapêutico , Cardiomiopatia Dilatada/diagnóstico por imagem , Cardiomiopatia Dilatada/tratamento farmacológico , Propanolaminas/uso terapêutico , Disfunção Ventricular Esquerda/diagnóstico por imagem , Disfunção Ventricular Esquerda/tratamento farmacológico , Adolescente , Fibras Adrenérgicas/diagnóstico por imagem , Antagonistas Adrenérgicos alfa , Cardiomiopatia Dilatada/complicações , Carvedilol , Criança , Pré-Escolar , Feminino , Imagem do Acúmulo Cardíaco de Comporta , Humanos , Lactente , Masculino , Compostos Radiofarmacêuticos , Resultado do Tratamento , Disfunção Ventricular Esquerda/etiologiaAssuntos
Anemia Falciforme/complicações , Isquemia Miocárdica/etiologia , Tomografia Computadorizada de Emissão de Fóton Único , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Isquemia Miocárdica/diagnóstico , Isquemia Miocárdica/fisiopatologia , Estudos Prospectivos , Volume SistólicoRESUMO
OBJECTIVES: We sought to assess the mechanism and significance of different (201)Tl redistribution patterns after successful primary stenting following acute myocardial infarction (AMI). BACKGROUND: The mechanism of (201)Tl reverse redistribution and the impact of different redistribution patterns on the recovery of contractility after successful reperfusion therapy for AMI remain unclear. METHODS: We studied 41 consecutive patients with successful primary stenting for a first AMI. Patients underwent predischarge and six-month follow-up dipyridamole stress-reinjection single photon emission tomography (SPECT), coronary and left ventricular angiography. Intracoronary Doppler assessment of coronary flow reserve (CFR) was performed before discharge. RESULTS: Four patient groups were identified according to predischarge SPECT: patients with I: nonreversible defects (n = 8), II: redistribution (n = 7), III: reverse redistribution (n = 21), IV: no defect (n = 5). At follow-up contractility recovery increased in a stepwise fashion from groups I to IV (19 +/- 41%, 40 +/- 53%, 70 +/- 28%, 78 +/- 33%, p = 0.01). Compared with patients with redistribution, those with reverse redistribution had lower infarct-related artery (IRA) CFR (2.2 +/- 0.5 vs. 2.8 +/- 0.9, p = 0.03) but higher contractility recovery. CONCLUSIONS: Variable (201)Tl redistribution patterns, early after successful stenting for AMI, may predict different degrees of late contractility recovery. The lower IRA CFR and the higher contractility recovery in areas with reverse redistribution suggest more severe microvascular dysfunction and less severe myocardial injury in such areas compared with those with redistribution.